María Natalia Gandur Quiroga: Key Takeaways from APCCC 2024
María Natalia Gandur Quiroga shared on X:
“SUPER TALK! Main take home messages from APCC: An update in 2024 by Silke Gillessen.
Key Takeaways from APCCC 2024
High-risk localized and locally advanced prostate cancer:
- For cN1 on conventional imaging: Consensus for RT prostate + pelvis + long-term ADT + Abiraterone for 2 years
- For cN1 disease on PSMA-PET only: Majority for the same option, 13% without Abiraterone, 16% for surgery
PSA Persistence Post RP:
- PSA 0.2: 56% recommend monitoring, 44% immediate therapy
- PSA 0.7: 62% recommend immediate therapy, 18% monitoring
Non-metastatic high-risk biochemical recurrence:
- EMBARK scenario defined by PSA doubling time ≤9 months amd PSA level ≥2 ng/ml after RT or ≥1 ng/ml post-RP
High-risk nmHSPC and oligometastatic disease:
- 70% recommend immediate systemic plus metastases-directed therapy
mHSPC Triplet Therapy:
Chemotherapy fit patients: 50% recommend triplet therapy (ADT + docetaxel + ARPI)
Treatment De-escalation:
- Deep remission: 47% recommend continuous therapy, 26% discuss interruption
BRCA2 Alteration in mCRPC:
- Consensus for ARPI + PARP inhibitor as 1st line
Lutetium-PSMA in mCRPC:
- Consensus for use after one ARPI + one taxane”
Source: María Natalia Gandur Quiroga/X
Maria Natalia Gandur Quiroga is a Medical Oncologist and Chief of the Division of Genitourinary Medical Oncology at the Instituto de Oncología Ángel H. Roffo in Buenos Aires, Argentina. She is a Professor of Medicine at the University of Buenos Aires at the Oncologists Post Graduates Studies.
Her research focuses on clinical trials with aims to improve the treatment of patients with urologic tumors. She is an active member of the European Association for Cancer Research, Argentinian Medical Association and American Society of Clinical Oncology.